Loading
DICER1 (Endoribonuclease Dicer) is an enzyme. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Lung cancer, Sarcomas, Brain and spinal cord tumours and 5 more.
Double-stranded RNA (dsRNA) endoribonuclease playing a central role in short dsRNA-mediated post-transcriptional gene silencing. Cleaves naturally occurring long dsRNAs and short hairpin pre-microRNAs (miRNA) into fragments of twenty-one to twenty-three nucleotides with 3' overhang of two nucleotides, producing respectively short interfering RNAs (siRNA) and mature microRNAs. SiRNAs and miRNAs serve as guide to direct the RNA-induced silencing complex (RISC) to complementary RNAs to degrade them or prevent their translation.
CIViC holds 31 clinical evidence items and 3 assertions across 15 variants. Open Targets scores its association with cancer at 0.87 (direct and indirect evidence; datatypes literature 0.99, genetic association 0.80, somatic mutation 0.85, genetic literature 0.92). IntOGen calls it a driver in 4 cohorts (1 activating, 3 loss-of-function), covering Colorectal Adenocarcinoma, Cutaneous Squamous Cell Carcinoma, Melanoma, Endometrial Carcinoma.
In plain words · DICER1 (Endoribonuclease Dicer) is an enzyme. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Lung cancer, Sarcomas, Brain and spinal cord tumours and 5 more.
DICER1 (Endoribonuclease Dicer) is an enzyme. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Lung cancer, Sarcomas, Brain and spinal cord tumours and 5 more.
Double-stranded RNA (dsRNA) endoribonuclease playing a central role in short dsRNA-mediated post-transcriptional gene silencing.
No product in this corpus aims at DICER1 yet. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
Tumour-specific alteration: the catalogues call it an oncogene driver (IntOGen cohort analysis finds it activated more often than chance) and a tumour suppressor (IntOGen finds it knocked out more often than chance), so the direction differs between cohorts but the alteration is somatic either way; what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA DICER1: RNA low tissue specificity; high antibody staining in 6 normal tissues; highest cancer staining urothelial cancer (7 of 11 high). Distribution: 7 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Lung cancer (all types), Sarcomas (soft tissue, bone, GIST), Brain and spinal cord tumours (all types), Ovarian cancer, Skin cancer (all types), Colorectal cancer, Endometrial cancer); Open Targets associates it with 7 specific cancer types at or above 0.5 (pleuropulmonary blastoma, goiter, multinodular 1, with or without Sertoli-Leydig cell tumors, global developmental delay - lung cysts - overgrowth - Wilms tumor syndrome, rhabdomyosarcoma, embryonal, 2, embryonal rhabdomyosarcoma, pineoblastoma and more). (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt Q9UPY3; CIViC gene DICER1; IntOGen DICER1; Human Protein Atlas DICER1 tissue; Open Targets ENSG00000100697 associations
First described 1999. Earliest sequence paper UniProt cites for the protein: Nagase et al, DNA Res, 1999, "Prediction of the coding sequences of unidentified human genes. XIII. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro". Source.
Sources: HGNC HGNC:17098 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q9UPY3 (protein name, function text, keywords and locations (REST API)); CIViC gene DICER1 (31 evidence items, 3 assertions, 15 variants; diseases: Sertoli-Leydig Cell Tumour, Gynandroblastoma, Anaplastic Sarcoma Of The Kidney, Pleuropulmonary Blastoma, Glandular Pattern Ovarian Yolk Sac Tumour and 3 more (GraphQL API, CC0)); Open Targets ENSG00000100697 (association with cancer (MONDO_0004992) 0.87; per-cancer scores at or above 0.5: non-small cell lung carcinoma 0.79, colorectal cancer 0.56, ovarian cancer 0.62, endometrial cancer 0.54, melanoma 0.62, sarcoma 0.79 (GraphQL API, CC0)); IntOGen DICER1 (driver in 4 cohorts (Act 1, LoF 3); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Double-stranded RNA (dsRNA) endoribonuclease playing a central role in short dsRNA-mediated post-transcriptional gene silencing. Cleaves naturally occurring long dsRNAs and short hairpin pre-microRNAs (miRNA) into fragments of twenty-one to twenty-three nucleotides with 3' overhang of two nucleotides, producing respectively short interfering RNAs (siRNA) and mature microRNAs. SiRNAs and miRNAs serve as guide to direct the RNA-induced silencing complex (RISC) to complementary RNAs to degrade them or prevent their translation. Gene silencing mediated by siRNAs, also called RNA interference, controls the elimination of transcripts from mobile and repetitive DNA elements of the genome but also the degradation of exogenous RNA of viral origin for instance. The miRNA pathway on the other side is a mean to specifically regulate the expression of target genes. Location: Cytoplasm; Cytoplasm, perinuclear region (UniProt). Locus 14q32.13 (HGNC).
RNA: low tissue specificity, detected in all normal tissues.
Medium: Bone marrow, Breast, Bronchus, Caudate, Cerebellum, Cerebral cortex, Colon, Duodenum.
Medium only: carcinoid, liver cancer, lymphoma, ovarian cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"DICER1" OR ABSTRACT:"DICER1" OR TITLE:"dicer 1, ribonuclease III" OR ABSTRACT:"dicer 1, ribonuclease III" OR TITLE:"Endoribonuclease Dicer" OR ABSTRACT:"Endoribonuclease Dicer" OR TITLE:"Dicer" OR ABSTRACT:"Dicer" OR TITLE:"KIAA0928" OR ABSTRACT:"KIAA0928" OR TITLE:"K12H4.8-LIKE" OR ABSTRACT:"K12H4.8-LIKE") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about DICER1, not a curated reading list.
Shares Brain and spinal cord tumours (all types), Skin cancer (all types), CIViC, IntOGen.
Shares Brain and spinal cord tumours (all types), Endometrial cancer, Skin cancer (all types), Ovarian cancer.
Shares Brain and spinal cord tumours (all types), IntOGen, Open Targets Platform.
Shares Pineoblastoma, Brain and spinal cord tumours (all types).
Shares Brain and spinal cord tumours (all types), Endometrial cancer, Ovarian cancer, Colorectal cancer.
Shares Brain and spinal cord tumours (all types), CIViC, Ovarian cancer, Open Targets Platform.
Shares Pineoblastoma, Brain and spinal cord tumours (all types).
Shares Pleuropulmonary blastoma (types I, Ir, II and III), Non-small-cell lung cancer.